Clinical Trial Update: A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2b study of UGN-102 for low-grade, intermediate-risk non-muscle-invasive bladder cancer has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• UGN-102 (UGN-102)

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-25